There is no current RSV vaccine available….
Moderna is looking for FDA approval this year for public use ….
The vaccine combats coughing and fever….
IT does NOT give people immunity from getting the RSV virus….
Moderna Inc (MRNA.O) said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults aged 65 and older. The disease surged in the United States and Europe this fall alongside the flu and COVID-19…..
…
The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.
Moderna’s study was conducted in about 37,000 participants aged 60 years and older. The data analysis was performed after 64 participants contracted RSV. The company plans to release the full data at a medical meeting.
Hoge said Moderna had started secondary analyses on the vaccine’s efficacy against more severe disease and hospitalization. He said it was too early to provide a potential price range for the vaccine it expects to be given annually.
The vaccine was generally found to be safe, with the most common side effects including injection-site pain, fatigue and headache. Hoge said there were no concerns of myocarditis, a type of heart inflammation linked to mRNA COVID vaccines….